newsfilter
← Latest News
GlobeNewswire·

Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

Sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trial Robust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatme